Development of a quality measures tool for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer: An integrated specialty pharmacy initiative
Restricted accessResearch articleFirst published online September, 2020
Development of a quality measures tool for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer: An integrated specialty pharmacy initiative
Tyrosine kinase inhibitors, commonly prescribed for non-small cell lung cancer, are efficacious but pose safety risks that can diminish quality of life. Quality measures to ensure appropriate utilization and monitoring of tyrosine kinase inhibitors are needed to reduce unnecessary healthcare costs and maximize therapeutic benefit. With integrated clinical and pharmaceutical care services, a health-system specialty pharmacy is the ideal setting for quality measures development.
Purpose
The purpose of this initiative was to develop a tool to assess quality in the utilization of tyrosine kinase inhibitors in non-small cell lung cancer by engaging multiple key stakeholder perspectives to identify the fundamental elements of high-quality clinical and specialty pharmacy care.
Summary
Quality measures for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer were developed by conducting package insert, guideline, and literature review followed by integrating feedback from key stakeholder groups through individual conversations and a structured assessment. The finalized guide assesses safety, efficacy, persistence, and patient-reported outcomes using defined clinical and specialty pharmacy measures. Most stakeholders agreed that the proposed measures were relevant as well as accurate and expressed support for implementation.
Conclusions
The proposed tool provides a framework for specialty pharmacies to deliver quality care in the use of tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Further work is needed to implement and validate this tool.
American Cancer Society. Cancer facts & figures 2019.
Atlanta:
American Cancer Society, 2019.
2.
ZappaCMousaSA.Non-small cell lung cancer: current treatment and future advances.Transl Lung Cancer Res2016;
5: 288–300.
3.
RolfoCPassigliaFOstrowskiM, et al.
Improvement in lung cancer outcomes with targeted therapies: an update for family physicians.J Am Board Fam Med2015;
28: 124–133.
4.
VanderLaanPARangachariDMajidA, et al.
Tumor biomarker testing in non-small-cell lung cancer: a decade of change.Lung Cancer2018;
116: 90–95.
5.
MitsudomiTMoritaSYatabeY, et al.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol2010;
11: 121–128.
6.
SequistLVYangJCYamamotoN, et al.
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol2013;
31: 3327–3334.
7.
ShawATKimDWNakagawaK, et al.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med2013;
368: 2385–2394.
8.
ZhouCWuYLChenG, et al.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011;
12: 735–742.
9.
AwDCTanEHChinTM, et al.
Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Asia Pac J Clin Oncol2018;
14: 23–31.
10.
HirshV.Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol2011;
18: 126–138.
11.
JoshiSSOrtizSWitherspoonJN, et al.
Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer2010;
116: 3916–3923.
12.
SkinnerKEFernandesAWWalkerMS, et al.
Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. J Med Econ2018;
21: 192–200.
13.
BergerJE.Quality in the pharmacy environment. Am Health Drug Benefits2008;
1: 7–8.
DarlingGMalthanerRDickieJ, et al.
Quality indicators for non-small cell lung cancer operations with use of a modified Delphi consensus process.Ann Thorac Surg2014;
98: 183–190.
16.
OuwensMMHermensRRTermeerRA, et al.
Quality of integrated care for patients with nonsmall cell lung cancer: variations and determinants of care. Cancer2007;
110: 1782–1790.
17.
SamsonPCrabtreeTBroderickS, et al.
Quality measures in clinical stage i non-small cell lung cancer: improved performance is associated with improved survival.Ann Thorac Surg2017;
103: 303–311.
18.
TanvetyanonTCormanMLeeJH, et al.
Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida.J Oncol Pract2011;
7: e25–e31.
19.
WangXSuSLiS, et al.
Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China.BMC Cancer2017;
17: 603.
20.
AndrawisMEllisonLTCCRiddleS, et al.
Recommended quality measures for health-system pharmacy: 2019 update from the Pharmacy Accountability Measures Work Group.Am J Health Syst Pharm2019;
76: 874–887.
21.
GantiAKOgaleSYangE, et al.
HSR20-084: real-world adherence and persistence of ALK inhibitors in non-small cell lung cancer (NSCLC). J Natl Compr Canc Netw2020;
18: HSR20-084.
22.
TimmersLBoonsCCMoes-Ten HoveJ, et al.
Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol2015;
141: 1481–1491.
23.
GebbiaVBellaviaMBannaGL, et al.
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.Clin Lung Cancer2013;
14: 390–398.
24.
TschidaSAslamSLalL, et al.
Outcomes of a specialty pharmacy program for oral oncology medications. Am J Pharm Benefits2012;
4: 165–174.
25.
CroweMLottS.Assessing outcomes like a PRO: how pharmacies can use patient-reported outcomes to better manage patients. Pharmacy Today, www.pharmacytoday.org/article/S1042-0991(15)30899-9/pdf (2014, accessed 8 March 2020).
26.
Genentech Inc. Alecensa (package insert).
South San Francisco:
Genentech Inc, 2018.
HarrisPATaylorRThielkeR, et al.
Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support.J Biomed Inform2009;
42: 377–381.
41.
AgeroALDuszaSWBenvenuto-AndradeC, et al.
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.J Am Acad Dermatol2006;
55: 657–670.
42.
PetrelliFBorgonovoKCabidduM, et al.
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer2012;
78: 8–15.
43.
CalifanoRTariqNComptonS, et al.
Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK.Drugs2015;
75: 1335–1348.
44.
MeloskyBLeighlNBRothensteinJ, et al.
Management of egfr tki-induced dermatologic adverse events.Curr Oncol2015;
22: 123–132.
45.
PellegrinoBFacchinettiFBordiP, et al.
Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature.Clin Lung Cancer2018;
19: e151–e161.
46.
SuhCHKimKWPyoJ, et al.
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis. Lung Cancer2019;
132: 79–86.
47.
KingSExleyJParksS, et al.
The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations.Qual Life Res2016;
25: 2245–2256.
48.
MorrisJPerezDMcNoeB.The use of quality of life data in clinical practice. Qual Life Res1998;
7: 85–91.
49.
HolleLMBoehnke MichaudL.Oncology pharmacists in health care delivery: vital members of the cancer care team.J Oncol Pract2014;
10: e142–e145.
50.
VulajVHoughSBedardL, et al.
Oncology pharmacist opportunities: closing the gap in quality care.J Oncol Pract2018;
14: e403–e411.
51.
BirandNBosnakASDikerO, et al. The role of the pharmacist in improving medication beliefs and adherence in cancer patients. J Oncol Pharm Pract2019;
25: 1916–1926.
52.
McKeeMFreiBLGarciaA, et al.
Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic.J Oncol Pharm Pract2011;
17: 387–394.
53.
IiharaHIshiharaMMatsuuraK, et al.
Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic.J Eval Clin Pract2012;
18: 753–760.
54.
ManciniRKasterLMVuB, et al.
Implementation of a pharmacist-managed interdisciplinary oral chemotherapy program in a community cancer center. J Hematol Oncol Pharm2011;
1: 23–30.
ShahNBJollyJAHorstSN, et al.
Development of quality measures for use of self-injectable biologic therapy in inflammatory bowel disease: an integrated specialty pharmacy initiative.Am J Health Syst Pharm2019;
76: 1296–1304.
61.
BagwellAKelleyTCarverA, et al.
Advancing patient care through specialty pharmacy services in an Academic Health System.J Manag Care Spec Pharm2017;
23: 815–820.
